ABT Stock: BTIG Reaffirms Buy Rating as Abbott Trades Near 52-Week Low
By TrendSpider Editor
BTIG analyst Marie Thibault confirmed a Buy rating on Abbott Laboratories with a price target of $131, signaling continued conviction even as the stock trades well below that level. ABT is currently priced at $93.13, representing a potential upside of roughly 40% to the analyst's target. The stock i
ABT Stock: BTIG Reaffirms Buy Rating as Abbott Trades Near 52-Week Low
BTIG analyst Marie Thibault confirmed a Buy rating on Abbott Laboratories with a price target of $131, signaling continued conviction even as the stock trades well below that level. ABT is currently priced at $93.13, representing a potential upside of roughly 40% to the analyst's target. The stock is hovering near its 52-week low of $90.72, far removed from its 52-week high of $139.05, making the analyst reaffirmation a notable show of confidence in the company's longer-term trajectory.
Key Drivers of the ABT Stock Move
- Main Catalyst: BTIG's Marie Thibault reiterated a Buy rating on ABT with an unchanged price target of $131, maintaining her prior target amid a period of significant price weakness for the stock.
- Bull Case: With ABT trading at $93.13 and a consensus average price target of $131, the stock carries substantial implied upside. The Buy confirmation from a named analyst adds credibility to the case that current price levels represent a dislocation from fundamental value.
- Bear Case: Despite the maintained Buy and a $131 price target, ABT has failed to find meaningful support, sitting just 2.41 points above its 52-week low of $90.72. An analyst holding a target unchanged rather than raising it offers little incremental reason for new buyers to step in aggressively.
ABT gained 2.19% in today's session, a modest bounce that still leaves the stock down dramatically from its 52-week high of $139.05. The reaffirmation from BTIG comes at a technically sensitive moment, with the stock compressed near multi-year support levels. If Abbott can hold above the $90.72 floor, the gap between current price and the $131 consensus target could begin to attract value-oriented investors. However, any deterioration in sector sentiment or company-specific news could quickly erase today's gains and test that critical low. The forward setup will depend heavily on whether upcoming fundamental catalysts, including product pipeline developments and any macroeconomic shifts affecting medtech demand, are enough to reverse the extended downtrend.
ABT Analyst Ratings and Price Targets
BTIG analyst Marie Thibault confirmed a Buy rating on Abbott Laboratories on April 27, 2026, keeping her price target steady at $131, unchanged from her prior target. The action reflects a maintenance of conviction rather than a reassessment. The consensus average price target across analysts currently stands at $131, aligning with BTIG's view and suggesting that the analyst community broadly sees significant recovery potential from current levels.
ABT Seasonality
Late April historically marks a period of renewed investor focus on medtech names as Q1 earnings reports are digested and forward guidance is evaluated. For a stock trading near its 52-week low, analyst reaffirmations during this window have historically acted as stabilizing signals heading into the summer months.
ABT Relative Performance
ABT's 2.19% gain today is a positive data point in isolation, but the stock's position near its 52-week low of $90.72, compared to a high of $139.05, indicates prolonged underperformance relative to where it traded earlier in the past year. Investors comparing ABT to broader medtech peers and the general market will note that the stock has surrendered a substantial portion of its prior range, making today's bounce a recovery attempt rather than a breakout.